Satiety
Founded Year
2000Stage
Series E | DeadTotal Raised
$79.65MLast Raised
$25.3MAbout Satiety
Satiety, Inc. is a medical device company focused on the development of less invasive devices for the treatment of obesity. Obesity is a global health problem, affecting 70 million people in the U.S. and 300 million worldwide, and growth of which is causing increases in obesity-related diseases such as diabetes, high blood pressure and cardiovascular disease. Obesity surgery has been shown to be the only long-term effective means of weight loss for morbidly obese patients. Satiety's first product, the TOGA System, enables physicians to perform a procedure similar to traditional restrictive obesity surgeries, but without surgical incisions. In this procedure, the TOGA System devices are inserted transorally (through the mouth) and are used to reduce the capacity of the stomach to give patients a feeling of fullness after a small meal. The procedure is intended to be safer and easier for patients to tolerate than conventional obesity surgery. Safety and effectiveness of the TOGA System are currently being evaluated in a multi-center U.S. Study and the system is not available for sale in the United States.
Loading...
Loading...
Satiety Patents
Satiety has filed 11 patents.

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
12/29/2006 | 5/28/2013 | Digestive system surgery, Gastrointestinal tract disorders, Digestive system procedures, Medical equipment, Digestive system | Grant |
Application Date | 12/29/2006 |
---|---|
Grant Date | 5/28/2013 |
Title | |
Related Topics | Digestive system surgery, Gastrointestinal tract disorders, Digestive system procedures, Medical equipment, Digestive system |
Status | Grant |
Latest Satiety News
Nov 10, 2020
Comparison of Low GI and High GI Potatoes in Relation to Satiety (POSAT) Brief The study is a single-blind, randomised crossover study, investigating how a high glycaemic potato affects satiety in humans compared to a low glycaemic potato. This is done to shed further light on the discussion about whether potatoes with a high glycaemic index increases the risk of overweight and obesity and thus indirectly type 2 diabetes and cardiovascular disease. Detailed The POSAT study follows a single-blinded randomized crossover design. Each subject will have two separate intervention days with at least a six-day washout period in between. On the two intervention days the subjects will be randomized into receiving a breakfast containing isocaloric amounts of either low or high GI potatoes. VAS will be measured 5 minutes before the meal, immediately after the meal is consumed and in intervals of 30 minutes thereafter until 2,5 hours after the initial meal. After this the subjects will be served a standardized homogenous ad libitum meal. The amount of food consumed will be registered. The subjects will be asked to fast for 8-10 hours prior to the trial days and abstain from vigorous physical activity and alcohol consumption for 2 days prior to each trial day. The trial will be conducted over a total of 8 days with 5-6 study subjects pr. trial day. The trial days will be spread out over a total of 2 weeks to allow for a 1-week washout period between trial days for each subject. Eligibility Exclusion Criteria: Use of daily prescription medicine (mild analgesics and antihistamines are allowed). Use of medicine or dietary supplements that can affect ones appetite one month before the start of the study. Smoking or have been smoking or using any nicotine products (gum or e-cigarette) within the last 3 months. Irregular smoking is allowed. Elite athletes defined as doing >10 hours of strenuous physical activity per week. Participation in other clinical studies <1 month before or during the study. Inability, physically or psychologically, to comply with the procedures required by the study protocol. Judged by the investigators. Any food allergies. Inability to complete the trial within 3 months after screening. Unable to fast 8-10 hours before the trial days. Healthy Volunteers: Accepts Healthy Volunteers Gender: Male
Satiety Frequently Asked Questions (FAQ)
When was Satiety founded?
Satiety was founded in 2000.
Where is Satiety's headquarters?
Satiety's headquarters is located at 2470 Embarcadero Way, Palo Alto.
What is Satiety's latest funding round?
Satiety's latest funding round is Series E.
How much did Satiety raise?
Satiety raised a total of $79.65M.
Who are the investors of Satiety?
Investors of Satiety include Venrock, Three Arch Partners, Morgenthaler Ventures, Pinnacle Ventures, HLM Venture Partners and 7 more.
Who are Satiety's competitors?
Competitors of Satiety include NuVasive, NeoChord, Vertos Medical, EndoGastric Solutions, Epitomee Medical and 7 more.
Loading...
Compare Satiety to Competitors
Varix Medical Corporation, located in Sunnyvale, Calif., is a medical device company focused on developing products for the minimally invasive treatment of chronic venous insufficiency, commonly referred to as "varicose veins." For patients with advanced stages of varicose veins, laser- and RF-based (radiofrequency) treatments have been developed, but each device has deficiencies making them less-than-optimal solutions. Varix Medical's platform technology will enable physicians to efficiently and effectively treat more types of diseased veins than is currently possible when using either laser or RF devices. Additional treatable vessels include tortuous sub-truncal vessels and other visible smaller varicose veins. The Varix platform employs a vapor-based endovenous ablation system that will consist of a disposable catheter, a catheter introducer or delivery system, and a reusable vapor generator. RCT and Coronis Medical Ventures LLC., formed Varix in August 2007 and acquired the technology under license from Tsunami MedTech LLC. Coronis and RCT have been the primary in investors in Varix.

Endologix is a company focused on the development and manufacturing of minimally invasive treatments for aortic disorders, operating within the medical devices industry. The company's main offerings include a variety of endovascular stent grafts, which are used for the treatment of abdominal aortic aneurysms (AAA), a condition characterized by a weakening of the wall of the aorta that can lead to a balloon-like enlargement. Endologix primarily serves the healthcare sector, particularly in areas related to vascular disease and aortic disorders. It was founded in 1992 and is based in Irvine, California.
CryoPen is a developer and manufacturer of state-of-the art medical devices and aesthetic treatment systems. CryoPen is committed to delivering the most effective, and profitable solutions available to healthcare providers, physicians of all specialties, and medical spas. The company's product portfolio aims to enable physicians to provide a higher quality of care and offer their patients a more diverse array of treatments while generating a substantial revenue stream for their practice. CryoPen's product set addresses a multitude of treatment applications such as laser hair removal, skin rejuvenation, cryosurgery, cellulite reduction, vascular lesions, pigmented lesions, acne, psoriasis, fine lines & wrinkles, scar and tattoo removal, photo facials, and skin tightening. With a dedication to the research and development of technologically advanced devices and equipment, every CryoPen product is designed to create a better patient experience, consistent clinical outcomes, and economic impact on the bottom line of their practice.
Axis Surgical Technologies, Inc. aims to develop, manufacture, and market devices that improve quality and efficiency in spinal surgery, especially for minimally invasive surgical techniques. Based in Mountain View, California, Axis offers an integration of visualization and articulation capabilities and provides spinal surgery equipment. Axis' FDA Grant In March 2010, Axis announced that it received 510(k) clearance from the Food and Drug Administration to market its C-MOR„ Visualization Device to use in diagnostic and operative arthroscopic and endoscopic procedures. This portable tool provides visualization and illumination of an interior cavity through either a natural or surgical opening. The ergonomic lightweight device also offers practitioners the convenience of endoscopic visualization and efficient one-handed operating ability; this device can be employed in hospital outpatient departments, ambulatory surgery centers, and office surgery suites.
BioSpiral's state-of-art system aims to provide prostate cancer treatment as a minimally invasive procedure, which uses cooling & heating technologies to destroy prostate cancer.nBioSpiral was established in Sep 2006 and is operating as part of NGT Incubator. nBioSpiral prostate thermodynamics therapy is an effective, minimally invasive treatment for prostate cancer that does not involve the difficulty and complications associated with surgery, nor the harmful properties of radiation or cryotherapy .The system revolutionizes prostate cancer treatment by introducing a "one shot" treatment method under local anesthesia at the physician's clinic. BioSpiral treatment is for patients with localized prostate cancer, who look for an effective minimal invasive therapy for prostate cancer. Additionally, this treatment can also be used by patients who have local recurrence after other treatments ("salvage" treatment). Key advantages:nCost effective: short treatment, no need for O.R or hospitalizationnHighly efficient: tissue ablationnPatients: high quality of life; minimal side effects, minimal invasive, short treatment & recovery.

Cardious is a medical device company organized to develop and commercialize the AvA Aortic Valve Bypass Graft System for use as a minimally invasive, beating heart alternative to traditional aortic valve replacement therapy.
Loading...